Literature DB >> 11070569

The role of statins in acute coronary syndromes: managing the unmet need.

G Jackson1.   

Abstract

Coronary heart disease is the major cause of death in the industrialised world. As the prevalence increases with advancing age, coronary heart disease will be a growing problem as the average age of the population increases. The cost of treatment following an acute coronary syndrome is considerable and there is a substantial risk of further episodes. However, there is much evidence that the disease is a dynamic and reversible process and further episodes are preventable. Numerous trials have shown the efficacy of statins in coronary heart disease. The most recent studies have shown efficacy in secondary prevention when statin therapy was started early (hours/days) after an acute episode. Although guidelines recommend that statin therapy should be initiated following an acute coronary syndrome, prescription rates seem to be static at around 40%. A number of measures need to be taken to improve the situation. Firstly, each hospital and coronary care unit should implement a clearly defined protocol delineating patient management following hospital admission. Provision of comprehensive discharge information should be a key feature of this communication. Secondly, regular audit of prescribing habits is essential to assess the situation. Finally, patient adherence to their regimen should be improved by collaborative involvement of doctor and patient in planning and implementing the treatment regimen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11070569

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  3 in total

Review 1.  Pharmacoeconomics of lipid-lowering drugs.

Authors:  Dean G Smith
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

2.  Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia.

Authors:  Jian-Jun Li; Ming-Zhe Chen; Xin Chen; Chun-Hong Fang
Journal:  Clin Cardiol       Date:  2003-10       Impact factor: 2.882

Review 3.  Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction.

Authors:  Joseph B Muhlestein
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.